Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.
Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future
Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.
Getting Personal With De Oro Devices’ Sidney Collin: ‘There’s A Lot Of Learning That Needs To Happen’
In this new series titled Getting Personal, we talk to new and veteran executives about the trials and tribulations in running a company while exploring their own motivations and passions. In this first edition, we talk to Sidney Collin, co-founder and CEO of De Oro Devices. Collin invented NexStride, a portable device to help overcome freezing of gait in Parkinson’s disease patients, while studying biomedical engineering at the California Polytechnic State University in 2018.
Exec Chat: 'Wow Factor' Is Important in Medtech Investment, But It’s Not Everything Says Ceros CEO
Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.
‘The Story That No One Likes To Hear’: Investors Looking For Surer Bets In Health Tech After Record 2021
A panel of investors and leaders in healtech expects investment in health tech to decline, but still foresees opportunities for companies working on solutions that will transform overall health care such as AI, ML, mental health and health equity.
‘Investee’ Eye: Quanta CEO’s Perspective Of Seeking And Obtaining $245m Raise
Quanta CEO John Milad outlines the transitional stage where a company begins to seek large-scale funding for the first time, and debates market valuations.
Investor Eye: Endeavour Vision Highlights Humanity Of Medtech, Invests In Unmet Needs
Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.
Investor Eye: Novalis Embraces Early Investment And Enabling Technology
Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.
Investor Eye: Octopus Ventures Tackles Tough, Taboo Problems In Health Care
In an interview with Medtech Insight, Octopus Ventures partner Pooja Sikka explained the approach Octopus takes to investments, and the key challenges the fund wants to address.
Investor Eye: Claudio D’Angelo Of RYSE Asset Management Explains Early-Stage Digital Health Investment
RYSE head tells Medtech Insight about his firm’s shift to investing in virtual primary care and telemedicine.
Investor Eye: Kyp Sirinakis, Epidarex Capital – ‘The Innovation Hunter’
In this edition of Investor Eye, Medtech Insight spoke to Kyp Sirinakis, managing partner at Epidarex Capital, a transatlantic fund investing in emerging life science hubs in the US and UK. The firm recently launched a new UK fund, Epidarex Capital III, for innovative UK start-ups.
Investor Eye: Sergey Young Searches For Investments That Extend Life
Sergey Young is on a mission to "extend healthy lifespans" by investing in longevity breakthroughs. Last year, the venture capitalist established a $100m fund investing in technologies with the potential to improve healthy long living.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.